Based on the preclinical information, we believe that adding NL-201 to pembrolizumab has the potential to provide increased benefits to patients, and we are excited to learn more through this part of the study.. Safety follow- up will occur within 7 days after the last dose of investigational product. Prior to that, Mr. Palekar served as President and CEO of Avanir Pharmaceuticals after a series of leadership roles in commercial and operations. These data, generated by our collaborators at the Fred Hutchinson Cancer Research Center, demonstrate robust immune effects and anti-myeloma activity in a challenging setting, said Priti Patel M.D., Chief Medical Officer of Neoleukin. Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Furthermore, NL-201 treated mice had an increase in bone marrow T-cells expressing granzyme B and a decrease in the T-cell exhaustion phenotype. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Patients will be able to receive study treatments as long as they are tolerated and there is evidence of clinical benefit. These statements are subject to numerous risks and uncertainties, including risks and uncertainties related to the companys cash forecasts, the companys ability to advance its product candidates, the receipt and timing of potential regulatory submissions, designations, approvals and commercialization of product candidates, the timing and results of preclinical and clinical trials, the timing of announcements and updates relating to the companys clinical trials and related data market conditions and further impacts of COVID-19, that could cause actual results to differ materially from what Neoleukin expects. Patients will then enter long-term follow-up until starting a subsequent therapy. SEATTLE, May 05, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., Neoleukin (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to designde novoprotein therapeutics, today announced dosing the first patient in a Phase 1 trial of NL-201 for advanced solid tumors. Furthermore, NL-201 has demonstrated both monotherapy and combination activity across a wide range of preclinical syngeneic tumor models. Patients will be able to receive study treatment as long as it is tolerated and there is evidence of clinical benefit. Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity usingde novoprotein design technology. MediaJulie Rathbun206-769-9219[emailprotected], InvestorsSolebury TroutAlexandra Roy617-221-9197[emailprotected], Neoleukin Therapeutics Announces Initiation of Phase 1 NL-201 Trial. Age-Related Macular Degeneration Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Bronchiectasis Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Schizophrenia Epidemiology Analysis and Forecast, 2021-2031. Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity usingde novoprotein design technology. Individual Participant Data (IPD) Sharing Statement: Studies a U.S. FDA-regulated Drug Product: Studies a U.S. FDA-regulated Device Product: Recommended phase 2 dose (RP2D) for NL-201 (Parts 1 and 2) [TimeFrame:Up to Day 33], Recommended dose schedule for NL-201 (Parts 1 and 2) [TimeFrame:Up to Day 33], Recommended phase 2 dose (RP2D) for NL-201 in combination with Pembrolizumab (Parts 3 and 4) [TimeFrame:Up to Day 33], Recommended dose schedule for NL-201 in in combination with Pembrolizumab (Parts 3 and 4) [TimeFrame:Up to Day 33], Incidence of treatment-emergent adverse events [TimeFrame:Up to Day 33], Severity of treatment-emergent adverse events [TimeFrame:Up to Day 33], Best Objective Response according to RECIST version 1.1 [TimeFrame:Up to 36 months], Objective Response Rate (ORR) according to RECIST version 1.1 [TimeFrame:Up to 36 months], Progression-Free Survival (PFS) according to RECIST version 1.1 [TimeFrame:Up to 36 months], Duration of Response (DOR) according to RECIST version 1.1 [TimeFrame:Upto 36 months], Pharmacokinetic (PK) profile of NL-201 by half-life (t1/2) [TimeFrame:Up to 24 Months], Pharmacokinetic (PK) profile of NL-201 by area under the plasma concentration time curve (AUC) [TimeFrame:Up to 24 months], Pharmacokinetic (PK) profile of NL-201 by maximum observed plasma concentration (Cmax) [TimeFrame:Up to 24 months], Pharmacokinetic (PK) profile of NL-201 by volume of distribution (Vd) [TimeFrame:Up to 24 Months], Immunogenicity of NL-201 [TimeFrame:Up to 24 months], Flow cytometry analysis of immune cells in blood [TimeFrame:Up to 36 months], Serum measurements of inflammatory cytokine levels [TimeFrame:Up to 36 months], Analysis of immune characteristics of the tumor microenvironment [TimeFrame:Up to 36 months], Estimate additional measures of anti-tumor activity of NL- 201 per iRECIST criteria [TimeFrame:Up to 36 months], Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, At least 6 weeks from any prior nitrosurea or mitomycin C therapy; at least 4 weeks from any other prior chemotherapy or checkpoint inhibitor; at least 2 weeks from any kinase inhibitor, Part 1 Only: Patients with relapsed or refractory advanced solid tumor, other than prostate cancer, who have progressed, not tolerated or are ineligible for all approved lines of therapy, Part 2 Only: Patients with kidney and skin cancer who have failed at least 1 line of systemic therapy, Part 3 Only: Patients with solid tumors who have received 1 prior line of therapy for advanced or metastatic disease, Part 4 Only: Patients with diagnosed target disease OR previously received pembrolizumab, Any serious medical condition or laboratory abnormality or psychiatric condition or any other significant or unstable concurrent medical illness (in the opinion of the Investigator) would preclude protocol adherence or would make the safety of the study drug difficult to assess, Known or suspected SARS-CoV-2 infection, unless patient tests negative for SARS-CoV-2 within the Screening period, History of solid organ transplant or bone marrow transplant, Prior CAR-T or allogeneic cellular therapy, Ongoing systemic immunosuppressive therapy. Neoleukin undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin currently plans to discuss its de novo protein pipeline during the second half of 2021. Tumor response to treatment will be assessed every 6 weeks for 12 weeks, and every 12 weeks thereafter until disease progression. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Patients will then enter long-term follow-up until starting a subsequent therapy. NL-201 is a de novo agonist of the IL-2 and IL-15 receptors, designed to expand cancer-fighting CD8 T cells and natural killer (NK) cells without any bias toward cells expressing the alpha receptor subunit (CD25). In November 2021, Neoleukin announced the presentation of four abstracts highlighting new preclinical data on NL-201 at the Society for Immunotherapy of Cancers 36TH Annual Meeting (SITC 2021). Based upon current internal infrastructure and pipeline initiatives, Neoleukin believes it has sufficient cash to fund operations into 2023. Gain on Sale of Aquinox Canada: The gain in the year ended 2020 relates to the sale of Aquinox Canada, a wholly owned subsidiary of Neoleukin. In January 2022, Neoleukin announced a clinical trial collaboration and supply agreement with Merck (known as MSD outside the United States and Canada). The presentation highlighted preclinical data on NL-201 alone and in several combination regimens. The Phase 1 study is planned to enroll up to 120 patients with advanced, relapsed, or refractory solid tumors. G&A Expenses: General and administrative expenses for the second quarter of 2021 increased to $5.3 million from $4.9 million for the second quarter of 2020. Neoleukin today announced the appointment of Rohan Palekar, Chief Executive Officer of 89bio, Inc. (NASDAQ:ETNB), to Neoleukin's Board of Directors, and the departure of Lewis "Rusty" Williams, MD, PhD, from the board. Neoleukin will host a conference call today to discuss 2021 financial results and provide a corporate update. Prespecified timepoints in serum before and after dosing with NL-201. For more information, please visit the Neoleukin website:www.neoleukin.com. NL-201 is Neoleukin's lead de novo protein therapeutic candidate, designed to mimic the therapeutic activity of natural cytokines IL-2 and IL-15, while potentially reducing the toxicities associated with high-dose IL-2. About NL-201NL-201 is ade novo agonist of the IL-2 and IL-15 receptors, designed to expand cancer-fighting CD8 T cells and natural killer (NK) cells without any bias toward cells expressing the alpha receptor subunit (CD25). U.S. Department of Health and Human Services. Further information on potential risk factors that could affect Neoleukins business and its financial results are detailed under the heading Risk Factors in documents the company files from time to time with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. NL-201 is ade novoagonist of the IL-2 and IL-15 receptors, designed to expand cancer-fighting CD8 T cells and natural killer (NK) cells without a bias toward cells expressing the IL-2 receptor alpha subunit (CD25). Part 3 and 4 Only: Known additional cancer that is progressing or has required active treatment within the past 2 years. Neoleukin undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Experimental results indicate that anti-myeloma activity is mediated by expansion of cytotoxic memory CD8 T cells and a decrease in T-regulatory CD4 cells in the bone marrow. We are excited to begin this trial to determine the optimal dose and schedule for NL-201 and evaluate its potential as a monotherapy to help cancer patients.. Details as follows: Time: 1:30 p.m. Pacific / 4:30 p.m. Eastern, Webcast URL: http://investor.neoleukin.com/events. According to the preclinical data, NL-201 showed the ability to elicit and expand CD8+ and NK cells at low doses with reduced impact on immunosuppressive regulatory T cells. Further information on potential risk factors that could affect Neoleukins business and its financial results are detailed under the heading Risk Factors in documents the company files from time to time with theSecurities and Exchange Commission(SEC), and other reports as filed with theSEC. In addition, the therapy was found to have monotherapy and combination activity across various preclinical syngeneic tumour models. Neoleukin chief medical officer Priti Patel said: We are pleased to begin the combination arm of our NL-201 trial and evaluate the potential to combine these two agents, which demonstrated encouraging preclinical anti-tumour activity in multiple tumour models. GlobalData exists to help businesses decode the future to profit from faster, more informed decisions. In December 2021, Neoleukin announced the presentation of preclinical data on NL-201 in multiple myeloma at the 63RDAmerican Society of Hematology (ASH) Annual Meeting and Exposition. Enrollment in the trial is progressing. Concurrent therapy with any other investigational agent, vaccine, or device. Tick the boxes of the newsletters you would like to receive. When the recommended dose and schedule are determined, Neoleukin expects to enroll indication-specific expansion cohorts of patients with renal cell carcinoma and melanoma. Further information on potential risk factors that could affect Neoleukins business and its financial results are detailed under the heading Risk Factors in documents the company files from time to time with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. Net Loss: Net loss for the year ended 2021 was $60.7 million compared to a net loss of $33.3 million for the year ended 2020. Study record managers: refer to the Data Element Definitions if submitting registration or results information. Interim data from the ongoing systemic Phase 1 trial of NL-201 is currently anticipated in 2022. This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. We believe it is the first fully de novo protein to enter clinical development, said Jonathan Drachman, M.D., Chief Executive Officer of Neoleukin. Listing a study does not mean it has been evaluated by the U.S. Federal Government. The trials combination arm will enrol up to 132 subjects. This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Parts 1 and 2 The primary purpose of this study is to understand the safety of NL-201 when given intravenously as monotherapy in patients with advanced cancer to evaluate tolerability and to identify a recommended dose and schedule for further testing. MediaJulie Rathbun206-769-9219jrathbun@neoleukin.com, InvestorsSolebury TroutAlexandra Roy617-221-9197aroy@soleburytrout.com, Condensed consolidated balance sheet data(In thousands of U.S. dollars), Condensed consolidated statements of operations(In thousands of U.S. dollars, except per share and share amounts), Neoleukin Therapeutics Announces Second Quarter 2021 Financial Results & Provides Corporate Update, Net loss per common stock basic and diluted, Basic and diluted weighted average common shares outstanding. Parts 3 and 4 If eligible, the patient will receive NL-201 and pembrolizumab treatment by vein. ET . NL-CVX1 is a de novo protein that binds to the spike protein of SARS-CoV-2, the virus that causes COVID-19 and blocks infection of human cells. NL-201 is a de novo protein designed to mimic the therapeutic activity of natural cytokines IL-2 and IL-15. Part 3 and 4 Only: History of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease. NL-201 is currently in a Phase 1 clinical trial for patients with solid tumors. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. Our progression to a clinical stage company is a significant milestone, and we remain focused on execution of our clinical development strategy and pipeline expansion as we advance and explore the potential of our de novo protein technology platform, said Jonathan Drachman, M.D., Chief Executive Officer of Neoleukin. The design and characterization of NL-CVX1 in under three months underscores the speed and versatility of Neoleukin'sde novo protein platform. Anti-drug antibodies in serum during and after treatment with NL-201, Based on Investigator assessment of imaging. In November 2021, Neoleukin delivered an oral presentation at the American College of Rheumatology Annual highlighting development of a potent and hyperstable computationally designed protein, Neo-5171, that blocks signaling by endogenous IL-2 and IL-15 with potential applications in inflammatory and autoimmune disorders. For more information, please visit the Neoleukin website:www.neoleukin.com. In addition to Neo-5171, Neoleukins discovery stage pipeline includes a Treg agonist targeting autoimmune and inflammatory conditions and a next- generation IL-2 / IL-15 agonist for oncology indications. Up to 132 patients will be enrolled in the combination arm of the study. In addition, Neoleukin is assessing plans for a local administration study of NL-201 while prioritizing the NL-201 systemic trial. NL-201 is currently in a Phase 1 clinical trial for patients with relapsed and refractory solid tumors to assess safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity. Neoleukins lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. Please remove one or more studies before adding more. Tumor response to treatment will be assessed every 6 weeks for 12 weeks, and every 12 weeks thereafter until disease progression. The increase was primarily due to increases in personnel-related costs. Previously presented preclinical data has demonstrated the ability ofNL-201 to stimulate and expand CD8+ and NK cells at low doses with minimal impact on immunosuppressive regulatory T cells. Cash Position: Cash and cash equivalents totaled $164.2 million as of June 30, 2021, compared to $192.6 million as of December 31, 2020. Experimental results indicate that anti-myeloma activity is mediated by expansion of cytotoxic memory CD8 T cells and a decrease in T-regulatory CD4 cells in the bone marrow. For more information, please visit the Neoleukin website: www.neoleukin.com. Mr. Palekar's career in the biopharmaceuticals industry spans more than 30 years, and he brings extensive strategic and operational experience spanning commercial and research and development functions. Mr. Palekar has served as the CEO of 89bio since June 2018. Additionally, a published abstract in Blood reported on NL-201 antitumor activity in preclinical studies of non-Hodgkin lymphoma. NL-201 is a computationally designed de novo protein that is a mimetic of natural cytokines IL-2 and IL-15 designed to expand cancer-fighting CD8 T cells and natural killer (NK) cells without a bias toward cells expressing the IL-2 receptor alpha subunit (CD25). These statements are subject to numerous risks and uncertainties, including risks and uncertainties related to the companys cash forecasts, the companys ability to advance its product candidates, the receipt and timing of potential regulatory submissions, designations, approvals and commercialization of product candidates, the timing and results of preclinical and clinical trials, the timing of announcements and updates relating to the companys clinical trials and related data market conditions and further impacts of COVID-19, that could cause actual results to differ materially from what Neoleukin expects. Neoleukin undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Patients will receive NL-201 as intravenous monotherapy to assess safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Neoleukins lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. Findings also indicated that local, intratumoral administration of NL-201 can control both the injected and distant tumors with improved tolerability compared to systemic administration in preclinical models. Choosing to participate in a study is an important personal decision. In 2022, we look forward to reporting interim data from our Phase 1 trial of NL-201, beginning a combination trial of NL-201 with pembrolizumab, initiating a Phase 1 trial of NL-201 in hematologic malignancies and continuing to pursue exciting avenues for additional de novo protein candidates.. This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Neoleukins lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. SEATTLE, March 01, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., Neoleukin (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results and a corporate update for the year ended December 31, 2021. Neoleukins lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. Interim data is expected to be reported in the second half of 2022. The increase was also due to facility-related costs associated with the build-out of Neoleukin's new headquarters and laboratory in Seattle, Washington. Net Loss: Net loss for the second quarter of 2021 was $15.1 million compared to a net loss of $9.7 million in the second quarter of 2020. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04659629. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the therapeutic properties and potential of the companys de novo protein design technology, the results of the clinical trial for NL-201, expectations regarding cash forecasts, and planned clinical and development activities and timelines. Furthermore,NL-201 has demonstrated both monotherapy and combination activity across a wide range of preclinical syngeneic tumor models. Parts 3 and 4 The primary purpose of this study is to understand the safety of NL-201 in combination with pembrolizumab when both drugs are given intravenously in patients with advanced cancer to evaluate tolerability and to identify a recommended dose and schedule for further testing. Patients will have tests and exams to see if they are eligible for the clinical trial. For general information, Learn About Clinical Studies. Neoleukin has multiple research projects underway evaluating the applications of de novo protein technology to develop agonists and antagonists of immune pathways. Keywords provided by Neoleukin Therapeutics, Inc.: Why Should I Register and Submit Results? R&D Expenses: Research and development expenses for the year ended 2021 increased to $39.2 million from $24.3 million for the year ended 2020. The gain of $7.8 million recognized was the total consideration of $8.2 million, less transaction costs of $0.4 million. The pharmaceutical industry's most comprehensive news and information delivered every month. MediaJulie Rathbun206-769-9219jrathbun@neoleukin.com, InvestorsSolebury TroutAlexandra Roy617-221-9197aroy@soleburytrout.com, Condensed Consolidated Balance Sheet Data(In thousands of U.S. dollars), Condensed Consolidated Statements of Operations(In thousands of U.S. dollars, except per share and share amounts), Neoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update, Net loss per common stock basic and diluted, Basic and diluted weighted average common shares outstanding. Neoleukin undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. *KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. "NL-201 is a novel immunotherapy that was computationally designed to overcome the limitations of native IL-2 by eliminating the alpha receptor binding interface. The increase in general and administrative expenses was primarily due to increases in personnel-related costs as Neoleukin continues to grow its operations. This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. While certain factors, including COVID-19, have had an impact on site activation for our Phase 1 trial of NL-201, we are accelerating site start-up activities to increase the pace of enrollment. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the therapeutic properties and potential of the companys de novo protein design technology, the results of the clinical trial for NL-201, expectations regarding cash forecasts, and planned clinical and development activities and timelines. Management will update timing for future trials as appropriate. NL-201 given as monotherapy by intravenous administration in indication specific cohorts at a dose and schedule determined in Part 1. Weve made significant strides in 2021 that will drive our efforts in 2022, including the start of clinical development for NL-201, the generation of preclinical findings supporting NL-201s activity in different indications and combinations, and highlighting new avenues for de novo protein design candidates and potential applications to expand our development pipeline, said Jonathan Drachman, M.D., Chief Executive Officer of Neoleukin. In May 2021, Neoleukin announced dosing of the first patient in a Phase 1 trial of NL-201. The agreement will allow for the evaluation of safety and efficacy of Neoleukins NL-201 in combination with Mercks anti-PD-1 therapy KEYTRUDA (pembrolizumab) in an ongoing Phase 1 trial. Keytruda is an anti-programmed death-1 (PD-1) therapy of Merck (known as MSD in North America). I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the, Introducing the Excellence Awards & Rankings 2022, The next chapter of clinical trial services. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the therapeutic properties and potential of the companys de novo protein design technology, the results of the clinical trial for NL-201, and planned clinical and development activities and timelines. The increase was partially offset by higher costs incurred in the second quarter of 2020 associated with the termination of its Vancouver, Canada office lease. Based upon current internal infrastructure and pipeline initiatives, Neoleukin believes it has sufficient cash to fund operations into the second half of 2023. R&D Expenses: Research and development expenses for the second quarter of 2021 increased to $9.8 million from $4.8 million for the second quarter of 2020. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the therapeutic properties and potential of the companys de novo protein design technology, the results of the clinical trial for NL-201, and planned clinical and development activities and timelines. A de novo agonist of the IL-2 and IL-15 receptors, NL-201 can extend cancer-fighting CD8 T cells and natural killer (NK) cells without having a bias toward cells expressing the alpha receptor subunit (CD25). - Interim data from NL-201 Phase 1 trial for patients with relapsed and refractory solid tumors anticipated in the second half of 2022 , - $142.5 million in cash and cash equivalents expected to provide runway into the second half of 2023 , - Appointment of Rohan Palekar to Board of Directors , - Company to host conference call today, March 1, 2022 at 1:30 p.m. PT / 4:30 p.m. Together with our published results on the preclinical activity of NL-201 against B-cell lymphoma, we believe that a clinical trial of NL-201 in patients with hematologic malignancies is warranted. MediaJulie Rathbun206-769-9219jrathbun@neoleukin.com, InvestorsSolebury TroutAlexandra Roy617-221-9197aroy@soleburytrout.com, Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd American Society of Hematology Annual Meeting (ASH 2021). The increase was primarily due to increased expenses incurred from IND-enabling and clinical trial activities related to Neoleukin's lead product candidate, NL-201, and in connection with the advancement of other Neoleukin technologies. Cash Position: Cash and cash equivalents totaled $142.5 million as of December 31, 2021, compared to $192.6 million as of December 31, 2020. Our preclinical studies have demonstrated activation of immune cells at low doses, potentially reducing the toxicities associated with high-dose IL-2. Parts 1 and 2 If eligible, the patient will receive NL-201 treatment by vein. Electronic Data Capture Solutions for Clinical Trials. SEATTLE, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., Neoleukin (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the second quarter ended June 30, 2021 and provided a midyear corporate update.